Alan Russell

Biohybrid Solutions Holding, Inc. is a company that focuses on delivering safe and effective biologic drugs to patients worldwide. The company has partnered with the US government on a $38m DTRA program, which includes the discovery, manufacturing, testing, and scale-up of nanoarmored™ drugs. The company is based in Sharpsburg, PA. The company's world-renowned scientists are spearheading innovations in protein therapeutics by solving a problem facing the pharmaceutical industry: how to create longer-lived, more effective medicine. The company has developed the immunocontrol ™ platform, which can be used for epitopetargeting ™ and epitopeaccentuation ™, allowing for the discovery of new drugs against secondary, silent epitopes. The company has also modified cancer-fighting mini-proteins to increase pharmacokinetics. Biohybrid Solutions Holding was founded in 2016 by Antonina Simakova, Alan Russell, and Krzysztof Matyjaszewski. Jean Pineault has been the CEO of the company since 2021.

Biohybrid Solutions Holding, Inc. is a company that focuses on delivering safe and effective biologic drugs to patients worldwide. The company has partnered with the US government on a $38m DTRA program, which includes the discovery, manufacturing, testing, and scale-up of nanoarmored™ drugs. The company is based in Sharpsburg, PA. The company's world-renowned scientists are spearheading innovations in protein therapeutics by solving a problem facing the pharmaceutical industry: how to create longer-lived, more effective medicine. The company has developed the immunocontrol ™ platform, which can be used for epitopetargeting ™ and epitopeaccentuation ™, allowing for the discovery of new drugs against secondary, silent epitopes. The company has also modified cancer-fighting mini-proteins to increase pharmacokinetics. Biohybrid Solutions Holding was founded in 2016 by Antonina Simakova, Alan Russell, and Krzysztof Matyjaszewski. Jean Pineault has been the CEO of the company since 2021.

Biohybrid Solutions Holding, Inc. is a company that focuses on delivering safe and effective biologic drugs to patients worldwide. The company has partnered with the US government on a $38m DTRA program, which includes the discovery, manufacturing, testing, and scale-up of nanoarmored™ drugs. The company is based in Sharpsburg, PA. The company's world-renowned scientists are spearheading innovations in protein therapeutics by solving a problem facing the pharmaceutical industry: how to create longer-lived, more effective medicine. The company has developed the immunocontrol ™ platform, which can be used for epitopetargeting ™ and epitopeaccentuation ™, allowing for the discovery of new drugs against secondary, silent epitopes. The company has also modified cancer-fighting mini-proteins to increase pharmacokinetics. Biohybrid Solutions Holding was founded in 2016 by Antonina Simakova, Alan Russell, and Krzysztof Matyjaszewski. Jean Pineault has been the CEO of the company since 2021.

Biohybrid Solutions Holding, Inc. is a company that focuses on delivering safe and effective biologic drugs to patients worldwide. The company has partnered with the US government on a $38m DTRA program, which includes the discovery, manufacturing, testing, and scale-up of nanoarmored™ drugs. The company is based in Sharpsburg, PA. The company's world-renowned scientists are spearheading innovations in protein therapeutics by solving a problem facing the pharmaceutical industry: how to create longer-lived, more effective medicine. The company has developed the immunocontrol ™ platform, which can be used for epitopetargeting ™ and epitopeaccentuation ™, allowing for the discovery of new drugs against secondary, silent epitopes. The company has also modified cancer-fighting mini-proteins to increase pharmacokinetics. Biohybrid Solutions Holding was founded in 2016 by Antonina Simakova, Alan Russell, and Krzysztof Matyjaszewski. Jean Pineault has been the CEO of the company since 2021.